Aav capsid variants targeting human glioblastoma cells
US-2022333136-A1 · Oct 20, 2022 · US
Core master regulators of glioblastoma stem cells
US11827884B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11827884-B2 |
| Application number | US-201816613402-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 15, 2018 |
| Priority date | May 15, 2017 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are immunotherapy compositions for treating a subject with a glioblastoma, comprising a peptide formulation derived from at least one cancer or stemness factor, nanoparticles containing peptides derived from at least one cancer or stemness factor, dendritic cells containing peptides derived from at least one cancer or stemness factors, RNA coding at least one cancer or stemness factor, nanoparticles containing RNA coding at least one cancer or stemness factor, dendritic cells containing RNA coding at least one cancer factor or stemness factor, or an inhibitor of at least one cancer or stemness factor. Also provided are methods of inhibiting a glioblastoma stem-like cell (GSC), methods of treating a subject for glioblastoma, and methods of reprogramming an astrocyte to a glioblastoma stem-like cell (GSC) using such immunotherapy compositions.
First claim
Opening claim text (preview).
That which is claimed: 1. A method of treating a subject with a glioma comprising administering a composition comprising a nucleic acid inhibitor that specifically targets at least one cancer factor comprising NKX6.2. 2. A method of treating a subject with a glioma comprising administering a composition comprising a nucleic inhibitor that specifically targets at least one cancer factor selected from the group consisting of BASP1, NKX6.2, and STOX2 and a nucleic acid inhibitor that specifically targets at least one stemness factor selected from SOX8, HES6, and ASCL1, and wherein the composition comprises nucleic acid inhibitors that specifically target each of BASP1, NKX6.2, MYCN, and ASCL1. 3. The method of claim 2 , wherein the composition further comprises nucleic acid inhibitors that specifically target each of SOX8 and OLIG2. 4. The method of claim 3 , wherein the composition further comprises nucleic acid inhibitors that specifically target each of STOX2 and HES6. 5. A method of inhibiting a glioblastoma stem-like cell (GSC) by introducing a composition that comprises a nucleic acid inhibitor that specifically targets at least one cancer factor comprising NKX6.2 into the GSC. 6. A method of inhibiting a glioblastoma stem-like cell (GSC) by introducing a composition that comprises a nucleic acid inhibitor that specifically targets at least one cancer factor and a nucleic acid inhibitor that specifically targets at least one stemness factor into the GSC, wherein the at least one stemness factor is selected from SOX8, HES6, and ASCL, and wherein the composition comprises nucleic acid inhibitors that specifically target each of BASP1, NKX6.2, MYCN, and ASCL1. 7. The method of claim 6 , wherein the composition further comprises nucleic acid inhibitors that specifically target each of SOX8 and OLIG2. 8. The method of claim 7 , wherein the composition further comprising nucleic acid inhibitors that specifically target each of STOX2 and HES6. 9. A method of inhibiting a glioblastoma stem-like cell (GSC) by introducing a composition that comprises a nucleic acid inhibitor that specifically targets at least one cancer factor and a nucleic acid inhibitor that specifically targets at least one stemness factor into the GSC, wherein the cancer factor is selected from the group consisting of BASP1, NKX6.2, and STOX2, and the stemness factor is selected from the group consisting of SOX8, HES6, and ASCL1, and wherein the nucleic acid inhibitor that specifically targets the cancer factor is an antisense molecule that targets a nucleic acid molecule having the sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 22, 24, 26 and 28, or a fragment thereof. 10. A method of inhibiting a glioblastoma stem-like cell (GSC) by introducing a composition that comprises a nucleic acid inhibitor that specifically targets at least one cancer factor and a nucleic acid inhibitor that targets at least one stemness factor into the GSC, wherein the cancer factor is selected from the group consisting of BASP1, NKX6.2, and STOX2, and the stemness factor is selected from the group consisting of SOX8, HES6, and ASCL1, and wherein the nucleic acid inhibitor that specifically targets the stemness factor is an antisense molecule that targets a nucleic acid molecule having the sequence of any of SEQ ID NOs: 14, 16, 40, 42 and 44, or a fragment thereof.
Assignees
Inventors
Classifications
- C12N15/1135Primary
against oncogenes or tumor suppressor genes · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
interfering nucleic acids [NA] · CPC title
Stem-loop; Hairpin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11827884B2 cover?
- Provided herein are immunotherapy compositions for treating a subject with a glioblastoma, comprising a peptide formulation derived from at least one cancer or stemness factor, nanoparticles containing peptides derived from at least one cancer or stemness factor, dendritic cells containing peptides derived from at least one cancer or stemness factors, RNA coding at least one cancer or stemness …
- Who is the assignee on this patent?
- Univ Florida
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1135. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).